Pearl Therapeutics Inc., a Redwood City, CA-based biopharmaceuticals company, has raised $65m in Series D financing.
The round was led by Vatera Healthcare Partners, with participation from existing investors 5AM Ventures, Clarus Ventures and New Leaf Venture Partners.
Founded in 2006 and led by Chuck Bramlage, chief executive officer, Pearl Therapeutics develops combination therapies for the treatment of highly prevalent respiratory diseases, including chronic obstructive pulmonary disease and asthma.
The company intends to use the capital to start Phase 3 for PT003, its lead candidate product comprised of glycopyrrolate (GP), a long-acting muscarinic antagonist (LAMA) and formoterol fumarate (FF), a long-acting beta-2 agonist (LABA) delivered via a metered dose inhaler (HFA MDI).
FinSMEs
13/11/2012